“BlueAllele Sues Intellia Therapeutics Over Patented Gene Editing Technology and Regeneron Collaboration”

Biotechnology company BlueAllele Corp. has filed a lawsuit against Intellia Therapeutics Inc. in Delaware federal court, alleging that Intellia’s gene editing technology infringes on three of its patents. BlueAllele asserts that Intellia has utilized the contested patents to generate over $100 million through a collaboration with Regeneron Pharmaceuticals Inc. The case underscores ongoing tensions in the biotech industry over intellectual property rights, particularly as companies vie for technological dominance and lucrative partnerships. For further details, click here.